Differential Risk of Cancer Associated with Glucagon-like Peptide-1 Receptor Agonists: Analysis of Real-world Databases

2021 ◽  
pp. 1-8
Author(s):  
Jiasheng Wang ◽  
Chang H. Kim
Keyword(s):  
Real World ◽  
Receptor Agonists ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1 ◽  
Risk Of Cancer ◽  
Differential Risk

Body Weight (BW) Outcomes with Canagliflozin 300 mg (CANA) vs. Glucagon-Like Peptide-1 Receptor Agonists (GLP-1s) in a Real-World (RW) Setting

Diabetes ◽  
2018 ◽  
Vol 67 (Supplement 1) ◽  
pp. 1291-P
Author(s):  
CRAIG I. COLEMAN ◽  
WILLIAM H. HERMAN ◽  
SHIVANI PANDYA ◽  
LI WANG ◽  
ONUR BASER ◽  
...  
Keyword(s):  
Body Weight ◽  
Real World ◽  
Receptor Agonists ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals Addition of or switch to insulin therapy in people treated with glucagon-like peptide-1 receptor agonists: A real-world study in 66 583 patients

2016 ◽  
Vol 19 (1) ◽  
pp. 108-117 ◽  
Author(s):  
Olga Montvida ◽  
Kerenaftali Klein ◽  
Sudhesh Kumar ◽  
Kamlesh Khunti ◽  
Sanjoy K. Paul
Keyword(s):  
Insulin Therapy ◽  
Real World ◽  
Receptor Agonists ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1

scholarly journals PDB119 GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS IN TYPE 2 DIABETES MELLITUS (T2DM): DATA FROM A REAL WORLD STUDY IN SPAIN

2019 ◽  
Vol 22 ◽  
pp. S594
Author(s):  
K. Norrbacka ◽  
A. Sicras-Mainar ◽  
I. Hernández ◽  
S. Tofé-Povedano ◽  
S. Díaz Cerezo ◽  
...  
Keyword(s):  
Diabetes Mellitus ◽  
Type 2 Diabetes ◽  
Type 2 Diabetes Mellitus ◽  
Real World ◽  
Receptor Agonists ◽  
Glucagon Like Peptide ◽  
Glucagon Like Peptide 1
Sign in / Sign up

Export Citation Format

Share Document